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Abstract 
 
BACKGROUND: Decision makers in middle income countries are using economic evaluations (EEs) in 
pricing and reimbursement decisions for pharmaceuticals. However, whilst many of these jurisdictions 
have local submission guidelines and local expertise, the studies themselves often use economic models 
developed elsewhere and elements of data from countries other than the jurisdiction concerned. The 
objectives of this study were to describe the current situation and to assess the challenges faced by 
decision makers in transferring data and analyses from other jurisdictions. 
METHODS: Experienced health service researchers in each region conducted an interview survey of 
representatives of decision making bodies from  jurisdictions in Asia, Central and Eastern Europe, and 
>ĂƚŝŶŵĞƌŝĐĂƚŚĂƚŚĂĚĂƚůĞĂƐƚŽŶĞǇĞĂƌ ?ƐĞǆƉĞƌŝĞŶĐĞŽĨƵƐŝŶŐƐ ? 
 
RESULTS: Representatives of the relevant organizations in 12 countries were interviewed. All 12 
jurisdictions had developed official guidelines for the conduct of EEs. All but one of the organizations 
evaluated studies submitted to them, but 9 also conducted studies and 7 commissioned them. Nine of 
the organizations stated that, in evaluating EEs submitted to them, they had consulted a study 
performed in a different jurisdiction. Data on relevant treatment effect was generally considered more 
transferable than those on prices/unit costs. Views on the transferability of epidemiological data, data 
on resource use and health state preference values were more mixed. Eight of the respondents stated 
that analyses submitted to them had used models developed in other jurisdictions. Four of the 
organizations had a policy requiring models to be adapted to reflect local circumstances. The main 
obstacles to transferring EEs were the different patterns of care or wealth of the developed countries 
from which most economic evaluations originate. 
 
CONCLUSIONS: In middle income countries it is commonplace to deal with the issue of transferring 
analyses or data from other jurisdictions. Decision makers in these countries face several challenges, 
mainly due to differences in current standard of care, practice patterns or GDP between the developed 
countries where the majority of the studies are conducted and their own jurisdiction 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
INTRODUCTION 
 
An increasing number of countries are using health technology assessment (HTA) to inform pricing and 
reimbursement decisions for new health technologies, especially pharmaceuticals. These HTAs normally 
incorporate and economic evaluation(EE), in which the costs of the new intervention are compared with 
their benefits(1). Although there are well-established methods for EE(2), derived in part from the 
underlying principles of welfare economics(3), there are still controversies concerning its use in health 
care decision-making(4), or its use for particular types of health care interventions(5). Despite these 
controversies, the use of EE is expanding worldwide, driven mainly by the need to use healthcare 
resources wisely, given the growing pressures on healthcare budgets. 
 
This paper explores the problems faced by decision-makers in middle income countries in attempting to 
use EEs to inform pricing and reimbursement decisions at the national or jurisdictional level. The 
conduct of a comprehensive EE requires a considerable amount of time and financial resources as well 
as technical expertise and data, all of which may pose challenges in these environments. Therefore, 
decision-makers in middle income countries may have to use analyses or data from other jurisdictions in 
their decision-making processes. While adapting or using EEs from other jurisdictions has the potential 
to save time and budget, inappropriate transfer evaluations can result in incorrect decisions which may 
delay patient access to the latest medical advances, or lead to an inefficient use of scarce health care 
resources. 
 
There is a growing literature on the transferability of economic evaluations. A good research practices 
task force established by the International Society for Pharmacoeconomics and Outcomes Research 
reviewed the various approaches for interpreting analyses or data from other jurisdictions and how they 
might be made relevant to the local context. The Task Force also reviewed the advice on dealing with 
transferability issues provided in various international methods guidelines for economic evaluation and 
made some recommendations for good practice(6,7). Since many economic evaluations employ 
decision-analytic models to estimate the costs and benefits of healthcare interventions(8), the most 
common approach is to attempt to re-populate the model with local data. 
 
Therefore the objectives of this paper are (i) to review the current practices of authorities in middle 
income countries in using economic evaluations from other jurisdictions in decision-making, using 
examples from select countries in Central and Eastern Europe, Latin America and Asia (ii)  to map out 
the various  methods of adaptation, examining the extent to which some middle income countries 
ƐŝŵƉůǇ ?ĐŽƉǇĂŶĚƉĂƐƚĞ ?Ɛ ?ǀĞƌƐƵƐƌŝŐŽƌŽƵƐůǇĂƐƐĞƐƐ the degree of transferability, following a scientific 
methodology for adapting studies to the local context  (iii) to consider  the various factors affecting the 
geographic transferability of EEs, focusing on the risks and limitations of using non-native economic 
models or data in local decision making and (iv) to  explore the obstacles to transferability and the 
potential solutions.  
 
METHODS 
 
In preparation for the study we reviewed the major publications on the transferability of economic 
evaluations, including the EUnetHTA Adaptation Checklist(9), the ISPOR Task Force Reports on the 
Transferability of Economic Evaluations Across Jurisdictions(6,7) , a review of existing checklists(10) and 
two papers discussing the use of economic evaluations in Latin America(11,12). We also consulted the 
websites of the key organizations using economic evaluation in decision-making concerning health 
technologies in the three regions of interest. The literature review was supplemented by structured 
interviews with representatives of the organizations concerned. Although several jurisdictions in middle 
income countries undertake health technology assessments, we wanted to concentrate on those 
jurisdictions where it was likely that decision-makers were partially reliant on economic evaluations 
conducted abroad. Therefore, the criterion for selecting the key organizations was that they were in 
jurisdictions that had been using economic analyses as part of their pricing and reimbursement 
processes for health technologies for at least one year. In each case an approach was made either to the 
director of the organization, or to the person heading the division dealing with economic evaluations, 
explaining the objectives of the research, the researchers involved and the source of funding for the 
study. In the majority of cases the person contacted participated in the interview themselves, although 
in some cases they designated one of their staff to be the respondent. 
 
An interview schedule with structured questions and response options was agreed among the study 
team and formed the basis of the interview.  Whenever feasible, the schedule was sent to interviewees 
in advance, so that they could prepare prior to the interview.  The interview covered the following areas 
(i) the role of the organization concerned in conducting or using economic evaluations, the expertise and 
skills of personnel available and the existence of methods guidelines for EEs; (ii) the current use of data, 
analyses of economic models from other jurisdictions and views on the transferability of each; and (iii) 
views on the main obstacles to the transferability. The list of obstacles was constructed based on our 
own experience of the problems of attempting to use economic evaluations conducted in other 
jurisdictions. (The interview schedule is available as a supplementary file.)
 
 
While the interview generally consisted of a series of close-ended questions there were also some open-
ended questions. However, as the researchers conducting the interviews were fairly experienced in their 
own region they further explored any responses that they felt required further clarification during the 
interview.  In addition, where possible, the information obtained was verified by the researchers 
themselves, and/or by consulting with other academic researchers in the jurisdictions concerned. In the 
ĐĂƐĞŽĨĚŝƐĐƌĞƉĂŶĐŝĞƐďĞƚǁĞĞŶƚŚĞŝŶƚĞƌǀŝĞǁĞĞ ?ƐƌĞƐƉŽŶƐĞƐĂŶĚƚŚĞƌĞƐĞĂƌĐŚĞƌ ?Ɛknowledge, a final 
response was agreed that adequately reflected the situation in the jurisdiction concerned. Therefore, 
while relying mainly on information reported by the organizations concerned, reasonable attempts were 
made to ensure its accuracy. 
 
RESULTS 
 
Sample of organizations studied 
 
Representatives were interviewed from the relevant organization in each of the following 12 countries 
from the three regions that met the inclusion criteria: Asia (South Korea, Taiwan and Thailand), Central 
and Eastern Europe (Croatia, Hungary, Poland and Slovakia), Latin America (Argentina, Brazil, Colombia, 
Mexico and Uruguay). In most cases the question of inclusion or exclusion was straightforward. 
However, there are a number of other countries, such as Chile, that have some experience of the use of 
economic evaluation, but have not yet incorporated it into a formal process for pricing and 
reimbursement of health technologies.  (The list of organizations surveyed is given in Table 1) 
 Table 1 about here 
   
Official methods guidelines for economic evaluation 
 
Methods guidelines for EEs are typically produced in jurisdictions that plan to use economic evaluations 
as part of an official decision-making process. Normally they are intended to be followed by both those 
making submissions and those evaluating them. Of the jurisdictions in our sample, all 12 had official 
guidelines, of which 5 had been developed by the organization surveyed.  
 
Role of the organizations surveyed 
 
The organizations surveyed could have one or more roles. First, they evaluate submissions of data or 
analyses from other parties, typically industry. Secondly, they could commission studies to be done by 
others, typically independent researchers. Finally, they could conduct their own EEs. The most common 
role was to evaluate studies submitted by others such as manufacturers (11 organizations), although 9 
organizations also conducted studies and 7 commissioned them. 
 
Uses of economic evaluations 
 
In some jurisdictions, economic evaluations are conducted in order to provide general information to 
inform resource allocation decisions. However, increasingly studies are being performed for a specific 
purpose.  It was found that the use of economic evaluations closely followed the role of the 
organizations themselves, with a strong emphasis on studies to inform reimbursement or coverage 
decisions (all 12 organizations). In addition, it can be seen a common use of EEs was also to inform price 
negotiations and decisions (8 out of 12), reflecting the trend towards considering price as a variable in 
cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐĂƐƐĞƐƐŵĞŶƚƐ ?ĂůƚŚŽƵŐŚŶŽƚŶĞĐĞƐƐĂƌǇŝŶĚŝĐĂƚŝŶŐƚŚĞĞǆŝƐƚĞŶĐĞŽĨĨŽƌŵĂů ?ǀĂůƵĞ-based 
ƉƌŝĐŝŶŐ ?ƐĐŚĞŵĞƐ ? 
 
Access to skills and expertise 
 
Any organization evaluating, commissioning or conducting HTAs or EEs requires access to personnel with 
a relevant range of skills and expertise. Many of the organizations had access to the relevant range of 
skills, such as physicians/clinical specialists (11 out of 12 organizations), pharmacists (10/12), health 
economists (10/12), medical statisticians (9/12) and epidemiologists (8/12).  
 
Use of international websites 
It is common for HTA bodies to consult several key websites in order to check whether particular 
assessments have been conducted in other jurisdictions, or more generally to search for evidence 
relating to the technology of interest (e.g. systematic reviews of the clinical evidence). The organizations 
studied reported that they considered a wide range of international websites. The 5 most frequently 
consulted websites were those of the National Institute of Health and Care Excellence (UK) (n=10) , the 
Centre for Reviews and Dissemination (UK) (n=6), the Canadian Agency for Drugs and Technologies in 
Health (n=4), the Scottish Medicines Consortium (n=4) and ƵƐƚƌĂůŝĂ ?ƐPharmaceutical Benefits Advisory 
Committee  (n=3). 
 
Use of studies from other jurisdictions 
 Of the 11 organizations whose role included evaluating economic evaluations, nine felt they had enough 
experience to answer the survey questions about their practice in consulting economic studies with 
content from another jurisdiction. Studies from other jurisdictions could potentially be used in a number 
of ways, ranging from a more general use to gain a better understanding of the background of the 
technology concerned or the decision problem in hand, to more specific uses, such as to check specific 
items of data. In the extreme, a study conducted elsewhere could be used as a basis for making a local 
decision if no local studies are available. Since the use of existing studies may vary from case to case, the 
organizations interviewed could give a graded respŽŶƐĞ ?ĨƌŽŵ ?KĨƚĞŶ ?ƚŽ ?EĞǀĞƌ ? ? Table 2 summarizes the 
responses obtained. It can be seen that, reassuringly, results from studies conducted in other 
jurisdictions were rarely used as the sole basis for making a local decision.  
 
Table 2 about here 
 
/ŶĂĚĚŝƚŝŽŶ ?ƚŚĞŽƌŐĂŶŝǌĂƚŝŽŶƐǁĞƌĞĂƐŬĞĚƚŽŶĂŵĞƚŚĞũƵƌŝƐĚŝĐƚŝŽŶƐƚŚĞǇŽĨƚĞŶƚƵƌŶĞĚƚŽĂƐĂ ?ƌĞĨĞƌĞŶĐĞ
ĐŽƵŶƚƌǇ ?ĨŽƌůŽĐĂůĚĞĐŝƐŝŽŶƐ ?dŚĞƌĞƐƉŽŶƐĞƐƚŽ this issue are interesting in that very rarely did 
respondents name countries within their own region. The three countries named as reference countries 
were the UK (8 times), Australia (5 times) and Canada (4 times)  
Use of transferability checklists 
All of the organizations studied reported that the economic evaluations submitted to them contained 
data generated in other jurisdictions. Several checklists have been developed to assist those wrestling 
with the challenges of adapting studies or data from other jurisdictions. Respondents were asked 
indicate whether they had consulted any of those checklists published in the literature. In general, the 
checklists were not used, with the EUnetHTA Adaptation Toolkit 
(www.hta.ac.uk/links/finaladaptationtoolkitnetscc.pdf) being the most frequently mentioned (i.e. by 3 
of the organizations studied). 
Perspectives on the use of data from other jurisdictions 
Previous studies(7) have shown that there are differing perspectives on the use of data from other 
jurisdictions. Sometimes there is an official position on the use of foreign data, stated in the 
ũƵƌŝƐĚŝĐƚŝŽŶ ?ƐŵĞƚŚŽĚƐŐƵŝĚĞůŝŶĞƐĨŽƌĐŽŶĚƵĐƚŝŶŐEEs. Nine of the organizations answered questions on 
this topic, relating to their role in evaluating economic evaluations, most commonly in industry 
submissions. Their views on the use and transferability of different categories of data are shown in Table 
3. 
 
Table 3 about here 
 
These responses are consistent with previous research in that data on relevant treatment effect are 
considered more transferable than those on prices/unit costs. The views on the transferability of 
epidemiological data, data on resource use and health state preference values are more mixed. With 
respect to the use of decision-analytic models from other jurisdictions, 8 of the 9 respondents to this 
question stated that analyses submitted to them had used models developed in other jurisdictions. In 
the majority of cases the models were adapted to reflect local circumstances, in some cases not. Only 4 
of the 9 oƌŐĂŶŝǌĂƚŝŽŶƐŚĂĚĂŶŽĨĨŝĐŝĂůƉŽůŝĐǇŽŶƚŚĞƵƐĞŽĨ ?ĨŽƌĞŝŐŶ ?ŵŽĚĞůƐ ?tŚĞƌĞƚŚĞƌĞǁĂƐĂŶŽĨĨŝĐŝĂů
policy, this was that models developed in other countries were acceptable, providing they were adapted 
to reflect local circumstances.   
 
Similar questions were asked of those organizations that stated that their activities in HTA included 
commissioning or conducting EEs. The responses to many of the questions were fairly similar to those 
given in the case of evaluating studies. For example, studies undertaken in other jurisdictions were 
always consulted, but the existing transferability checklists were rarely used. However, in commissioning 
or conducting local studies there was a slightly lower tendency to use foreign data or foreign models, 
with a greater emphasis on using local data and analyses.  
 
Obstacles to transferring studies from other jurisdictions 
 
Finally, respondents were asked to select from a list of potential obstacles to transferring data or 
analyses from other jurisdictions. The most frequently selected obstacles are shown in Table 4. It can be 
seen that the most important obstacles are those relating to the differences in current standard of care, 
practice patterns or GDP between the developed countries where the majority of these studies are 
conducted and those jurisdictions that have a need to make local decisions. The second most important 
group of obstacles relate to inadequacies in reporting, including the lack of access to electronic copies of 
models. 
 
Table 4 about here 
 
 
DISCUSSION  
Although this study covered only 12 countries in Asia, Central and Eastern Europe and Latin America, 
these countries represent the only jurisdictions in these regions ƚŚĂƚŚĂǀĞŚĂĚŵŽƌĞƚŚĂŶŽŶĞǇĞĂƌ ?Ɛ
experience with the formal use of economic evaluations in the pricing and reimbursement of 
pharmaceuticals. Therefore, this study should be viewed as a pilot study. However, whilst one must be 
careful of extrapolation, the experience of these organizations in dealing with the challenges of using 
studies or data from other jurisdictions may be predictive of the issues that other jurisdictions will face 
in the future, as they begin to use economic evaluations in their decision-making processes. 
Main findings 
First, establishing the infrastructure to use economic studies in pricing and reimbursement decisions 
does not seem to be a major problem. Most of the organizations studied had access to the appropriate 
set of skills and were in jurisdictions where official guidelines have been established for the conduct of 
studies. However, previous research(13) suggests that the processes for conducting and evaluating HTAs 
(including economic evaluations) might need close scrutiny. That is, how good is the technical review of 
company submissions, how extensively are stakeholders involved and how transparent is the process? 
Audit criteria for HTA organizations conducting HTA to inform resource allocation decisions have been 
previously suggested(14). 
Secondly, HTA organizations in these regions do look to external resources when undertaking their 
activities, by consulting websites and locating studies conducted in other jurisdictions. This is probably 
no different from the practice of HTA organizations in Western Europe and North America. However, 
one key difference is that the jurisdictions where the majority of studies are conducted often have 
different treatment patterns and resource availability than the jurisdictions covered in this study. 
Indeed, ƚŚĞƌĞƐƉŽŶĚĞŶƚƐƌĞƉŽƌƚĞĚƚŚĂƚƚŚĞǇŵŽƐƚůǇƚƵƌŶĞĚƚŽĚĞǀĞůŽƉĞĚĐŽƵŶƚƌŝĞƐĂƐ ?ƌĞĨĞƌĞŶĐĞ ?
countries for their decisions, as opposed to countries within their own region, probably reflecting the 
fact that economic evaluations of the technology of interest were much more likely to exist in developed 
countries than in other middle income countries, even if the latter jurisdictions were considered to be 
more relevant. It is also possible that evaluation reports from the countries named were readily 
available and/or considered to be reliable. 
This implies that issues relating to the transferability of economic evaluations are likely to be important. 
Therefore, it is somewhat surprising that the organizations studied had made very little use of existing 
transferability checklists. One explanation offered was that issues of transferability were adequately 
handled by local submission guidelines, so it was unnecessary to apply a checklist to the studies 
submitted. Another potential explanation is that HTA organizations in middle income countries rarely 
have direct access to the economic models as applied in other jurisdictions. Therefore they cannot 
assess directly the transferability of international economic models. On the other hand, the 
transferability of economic models can more easily be assessed by those organizations conducting 
economic evaluations, as opposed to those organizations that merely undertake a critical appraisal of 
submitted models only after partial or full local adaptation.    
Thirdly, the economic evaluations submitted to the organizations studied here often contain models 
developed in other jurisdictions and data from other countries. With respect to the models, the 
prevailing view is that they normally require adaptation to local circumstances and half the 
organizations that evaluate manufacturer submissions had official policies on this matter. However, 
ŵŽƌĞĐŽŶƐŝĚĞƌĂƚŝŽŶŝƐƌĞƋƵŝƌĞĚŽĨǁŚĂƚ ?ĂĚĂƉƚĂƚŝŽŶ ?ĞŶƚĂŝůƐĂŶĚŚŽǁŽŶĞǁŽƵůĚĚĞƚĞƌŵŝŶĞƚŚĞ
appropriate amount of adaptation in a given situation. A key issue is whether the adaptation required is 
confined merely to re-populating the model with local data (where available), or whether it extends to 
changing the model structure. The latter has more far-reaching consequences for technology 
manufacturers operating on a global level. More case studies are required in order to address this issue. 
Turning to the data, the perceptions on the transferability of different categories of data mirrored the 
statements in official methodological guidelines for economic evaluation(7). By and large, the 
perceptions expressed were consistent and understandable, although more exploration of the 
transferability of relative treatment effect is probably required. For example, in some cases, the 
treatment effect seen in clinical studies undertaken in Western Europe and North America may be 
different (higher or lower) in middle-income countries because of differences in health care provision. 
However, paradoxically, more clinical trials of pharmaceuticals are now being conducted in Asia, Central 
and Eastern Europe and Latin America, primarily for financial reasons. 
Fourthly, the analysis of the major obstacles to the transferability of foreign data or analyses showed 
that concerns about the differences in health care resources and practice patterns were the major 
reasons why respondents questioned whether studies conducted in other jurisdictions were relevant to 
their setting. Many of these issues could be handled by re-populating models with local data. However, 
if the concern is that the current standard of care in the country of interest was not compared with the 
new technology in the existing clinical trials, this implies the use of network meta-analysis(15,16), with 
the resulting, unavoidable, uncertainties.   
As the use of economic evaluations to inform reimbursement and coverage decisions increases in 
middle income countries, this study suggests that it will be increasingly important to ensure improved 
practices in evaluating and conducting transferability of foreign data.  Inadequacies in dealing with 
transferability issues may lead to inaccurate estimates of the local cost-effectiveness of technologies, 
resulting in inappropriate coverage decisions and the inefficient use of healthcare resources. 
Limitations of the study  
The main limitation of the study is that, at present, relatively few jurisdictions in middle income 
countries are formally using economic evaluations in reimbursement and pricing decisions for health 
technologies. Therefore, current experience with using economic evaluations conducted elsewhere is 
quite limited. Secondly, the findings of our study are mainly based on interviews with key country 
experts, with the inherent shortfalls of the survey approach.  However, the researchers conducting the 
interviews did their best to verify the responses and there is no a priori reason to suspect that biases in 
the responses could have been introduced, either through the objectives of the study or its funding. 
Recommendations to those evaluating economic evaluations  
What could local HTA organizations do in order to improve on their use of economic evaluations 
conducted elsewhere? Certainly, they could make more use of the current published transferability 
checklists
10
. In addition, they could consider investing in local data generation for those categories of 
data normally considered to have low transferability, such as unit costs, health state preference values  
and epidemiological data. Also, as the number of HTA organizations in middle income countries 
increases, they could collaborate more fully within their region, since the transferability of economic 
evaluations within the region is likely to be greater than that between regions. Finally, although the 
organizations studied reported that they had access to a wide range of skills, there probably still a need 
to invest in training in the relevant expertise in economic evaluation, as its use in reimbursement and 
coverage decisions increases. 
Recommendations to those conducting economic evaluations 
Technology manufacturers operating on the global level could try to gain a better understanding of the 
operation of health care systems in Asia, Central and Eastern Europe and Latin America in order to gain 
a greater appreciation of the likely problems in the transferability of studies. In addition, when 
developing a global decision-analytic model, they could better anticipate the need for local adaptation, 
including the possibility that the model structure may need to be adapted. They could also, invest in 
data themselves, either as individual companies, or collectively within a given disease area (e.g. in 
generating unit costs or epidemiological data relevant to the disease in question). The fact that 
respondents in this study reported that they placed a lower reliance on foreign data when developing 
their own models suggests that there may be a greater possibility of making studies locally relevant than 
is exhibited in some of the studies submitted to HTA organizations for evaluation. 
 
Many of these initiatives could be better pursued if there were more active engagement between 
manufacturers and decision-makers in these regions. This interaction has greatly increased in Europe in 
recent years, but requires a certain degree of trust on all sides. However, one might expect it to increase 
in the jurisdictions studied as decision-makers gain more experience with the use of economic 
evaluations in their decision-making processes.  
CONCLUSIONS 
In the jurisdictions studied, it is commonplace to deal with the issue of transferring analyses or data 
from other jurisdictions in order to inform reimbursement of pricing decisions. Decision makers in these 
countries have used data or analyses from foreign studies in a number of ways. They are aware of the 
various factors affecting the geographic transferability of economic evaluations. However, they face 
several challenges, mainly due to differences in current standard of care, practice patterns or GDP 
between the developed countries where the majority of the studies are conducted and their own 
jurisdiction. Knowing these issues, there are several actions that those conducting or evaluating 
economic evaluations could do in order to increase their transferability. 
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Appendix 1 List of Organizations Surveyed 
Asia 
 South Korea- Health Insurance Review and Assessment Servire 
 Taiwan- Center for Drug Evaluation 
 Thailand- Health intervention and Technology Assessment Program 
Central and Eastern Europe 
 Croatia- Agency for Quality Accreditation in Health Care and Social Welfare 
 Hungary- Office of Technology Assessment, National Institute for Quality 
 and Organizational Development in Healthcare and Medicines 
 Poland- Agency for Health Technology Assessment in Poland 
 Slovakia- Working Group for Pharmacoeconomics, Clinical Outcomes and 
 HTA, Slovak Ministry of Health 
Latin America 
 Argentina- UCEETS, National Ministry of Health 
 Brazil- National Commission for the incorporation of Technologies 
 (CONITEC) 
 Colombia- IETS 
` Mexico- General Health Council 
 Uruguay- FNR 
